EquiTech Corporation Announces Patent Pending Enhanced Absorption Technology and Pharmaceutical Products

EDMONTON, ALBERTA--James Chivers-Wilson President and CEO of EquiTech is pleased to announce that on behalf of EquiTech and its key inventor, Dr. Fakhreddin Jamali, three U.S. and two international patent applications have been filed on the Corporation's lead compounds and innovative research tools to evaluate new pharmaceutical formulations. EquiTech's enhanced absorbing technology, as demonstrated in the lab, enables the Company's lead compounds to provide more pain relief faster, compared to existing over-the-counter pain relief medication evaluated by company scientists. A scientifically designed clinical trial in humans is EquiTech's next step in bringing the lead compound closer to market.

Dr. Jamali the VP of Research and Chief Scientific Officer has published over 160 refereed scientific articles and is recognized world-wide for his expertise in the pharmacology and reformulation of analgesic, anti-rheumatic, and cardiovascular drugs.

EquiTech is a publicly listed biopharmaceutical company with patent pending technology to create and develop better absorbing pharmaceutical products that are taken orally. EquiTech's lead compound is a fast absorbing oral medication for the treatment of moderate acute pain.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction. The securities of the corporation have not been and will not be registered under the U.S. Securities Act, 1933, as amended and subject to certain exemptions may not be offered or sold in the United States or to U.S. persons. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT: